Adaptive Biotechnologies (NASDAQ: ADPT) CCO trades 1,299 shares under plan

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 1,299 shares of Common Stock on July 30, 2026 at $24.00 per share in an open-market or private transaction. Following this sale, she directly holds 399,989 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2025, indicating it was executed under a pre-arranged trading framework.

Insider Trade Summary 10b5-1

Net Seller: 1,299 shares

Net Sell 1 txn

Insider BOBULSKY SUSAN

Role Chief Commercial Officer, MRD

Sold 1,299 shs ($31K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,299	$24.00	$31K

Holdings After Transaction: Common Stock — 399,989 shares (Direct)

Footnotes (1)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

Key Figures

Shares sold: 1299.0000 shares Sale price: 24.0000 USD per share Shares owned after sale: 399989.0000 shares

3 metrics

Shares sold 1299.0000 shares Common Stock sold on July 30, 2026

Sale price 24.0000 USD per share Price per share for the July 30, 2026 sale

Shares owned after sale 399989.0000 shares Direct Common Stock holdings following the transaction

Key Terms

Rule 10b5-1 trading plan, open market or private transaction

2 terms

Rule 10b5-1 trading plan regulatory

"The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 06:27 PM Accepted by SEC EDGAR 08/03/2026 - 06:26 PM Learn about SEC filing dates

FAQ

What insider sale did Adaptive Biotechnologies (ADPT) disclose?

Adaptive Biotechnologies disclosed that Chief Commercial Officer, MRD, Susan Bobulsky sold 1,299 shares of Common Stock at $24.00 per share on July 30, 2026. After this transaction, she directly holds 399,989 shares in the company.

Who is the insider involved in the latest ADPT Form 4 transaction?

The insider is Susan Bobulsky, Adaptive Biotechnologies’ Chief Commercial Officer, MRD. She reported selling 1,299 shares of Common Stock at $24.00 per share and now directly owns 399,989 shares following this transaction.

How many Adaptive Biotechnologies (ADPT) shares were sold and at what price?

The reported transaction involved the sale of 1,299 shares of Adaptive Biotechnologies Common Stock at a price of $24.00 per share. This was characterized as a sale in an open market or private transaction.

How many ADPT shares does the insider own after this transaction?

After the reported sale, Chief Commercial Officer, MRD, Susan Bobulsky directly owns 399,989 shares of Adaptive Biotechnologies Common Stock. This figure reflects her holdings immediately following the July 30, 2026 transaction.

Was the ADPT insider sale made under a Rule 10b5-1 trading plan?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Susan Bobulsky on December 16, 2025, meaning the trades were pre-arranged under SEC rules rather than initiated on an ad hoc basis.

What type of security was involved in the Adaptive Biotechnologies (ADPT) transaction?

The transaction involved Common Stock of Adaptive Biotechnologies. A total of 1,299 shares were sold at $24.00 per share, and the reporting person’s direct ownership after the sale stands at 399,989 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBULSKY SUSAN

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer, MRD

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2026		S(1)		1,299	D	$24	399,989	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

	Susan Bobulsky by Kyle Piskel, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)